Disc Medicine Stock News

WATERTOWN, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the pricing of an upsized underwritten public offering of shares of its common stock. Disc is selling 6,...

WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the commencement of an underwritten public offering of $350 million of shares of its common stock and, i...

Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clinical trial met every primary and secondary endpoint, strengthening the firm's case for another FDA submission.

Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.

Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on Monday after its experimental drug bitopertin met every endpoint in a pivotal phase 3 trial. The APOLLO trial results strengthened the prospects for bitopertin as a treatment for erythropoietic protoporphyria (EPP), a rare disease that causes severe pain and skin reactions when patients are expose...

Disc Medicine said on Monday its experimental pill for a rare disease that causes ​extreme pain from sunlight met all of ‌its main and secondary goals in a late-stage trial, sending its shares surging 65% in premarket trading.

Positive APOLLO trial topline results demonstrated statistically significant and clinically meaningful benefit across all study endpoints Successfully met co-primary endpoints of reduction in protoporphyrin IX (PPIX) and increased total time in light All secondary endpoint results were also positive and statistically significant, including reductions in phototoxic reactions and improvements on ...

WATERTOWN, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presented positive initial results from the RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia vera (PV)...